Jill Feldman/henryford.com
Jun 24, 2025, 16:35
Jill Feldman: Hope for EGFR+ NSCLC after Prior EGFR-directed Therapy and Platinum-based Chemotherapy
Jill Feldman, Lung Cancer Patient and Advocate, and Co-Founder of EGFR Resisters, shared a post on X by Oncology Brothers, adding:
“Accelerated approval for Dato-DXd for EGFR+ NSCLC after prior EGFR-directed therapy and platinum-based chemotherapy.
Treatment options = HOPE – if a patient is able to tolerate and stay on the treatment.
QOL Matters. Please see guidance below on side effect management.”
Quoting Oncology Brothers’ post:
“Datopotamab deruxtecan (DatoDXd – Trop2 ADC) now FDA Oncology approved off TROPIONLung01 and 05 for previously treated mEGFR NSCLC
ORR of 42.7%, mDoR 7.0 mos
mPFS: 5.8 mos and mOS 15.6 mos
AEs: Nausea, stomatitis, and ILD
Some guidance on side effect management for DatoDXd (based on review article from Dr. Heist, Aditya Bardia et al., as this is also approved for HR+ breast cancer)!
Watch out for ILD, Mucositis, IRR, and Ocular toxicities.”
Title: Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan
Authors: Rebecca S Heist, Jacob Sands, Aditya Bardia, Toshio Shimizu, Aaron Lisberg, Ian Krop, Noboru Yamamoto, Takahiro Kogawa, Saba Al-Hashimi, Simon S M Fung, Anat Galor, Francesca Pisetzky, Priyanka Basak, Cindy Lau, Funda Meric-Bernstam
You can read the Full Article in Cancer Treatment Reviews.
More posts featuring Jill Feldman and Oncology Brothers.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 24, 2025, 15:53
Jun 24, 2025, 11:46
Jun 24, 2025, 10:32